Tripeptide · Fact sheet

KPV

Also known as Lys-Pro-Val

KPV is a three-amino-acid peptide investigated for inflammatory signaling, especially in the gut. Cell and mouse results are promising research leads, but human treatment benefits and safety have not been established.

Preclinical researchMostly animal or lab research

What is KPV?

KPV corresponds to the final three amino acids of alpha-melanocyte-stimulating hormone. Researchers have studied how a peptide transporter brings it into cells.

Benefits & claims

Readers look for relief from gut inflammation, skin irritation, and broad inflammatory symptoms. These claims extend beyond the human evidence available in the cited research.

What the evidence supports

  • KPV reduced inflammatory signaling and disease measures in experimental colitis models.
  • A mouse cancer model offers a mechanistic lead, not evidence that KPV prevents or treats human cancer.
Research areas
  • Inflammatory signaling
  • Experimental colitis
  • Colitis-associated cancer models

Dosage & frequency

No established human regimen

KPV evidence is preclinical and does not establish a human inflammatory-bowel or skin-treatment dose.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • This short alpha-MSH fragment is not an approved corticosteroid or anti-inflammatory drug.

Interactions & precautions

  • Human drug-interaction studies have not established compatibility for this preclinical peptide.

What is still unresolved

  • Human route, exposure, clinical efficacy, repeated-use safety, and interactions remain unestablished.

Side effects & risks

  • FDA reports no identified human exposure data and insufficient safety information.
  • A useful human side-effect frequency cannot be calculated from cell or mouse experiments.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Mostly animal or lab research

The central findings come from cell systems and mouse models of colitis and inflammation-associated cancer. Human biopsy observations in a paper are not a trial of KPV treatment.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

Slightly more energy, no broader symptom change

A commenter with self-described mast-cell symptoms reported a month of oral KPV with slightly more energy, but no change in those symptoms or other problems.

Reported use in this account

Product
Product described as oral KPV
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Oral
Duration
One month

Diagnosis, formulation and other treatments were not verified. A subjective energy change does not establish treatment of mast-cell disease.

Read the month-long comment
Negative account · personal report

Bloating, mood swings and fatigue

A different commenter described brief symptom relief followed by worsening symptoms. Their follow-up reported bloating and mood swings with oral exposure, and marked fatigue with a different formulation.

Reported use in this account

Product
Products described as KPV
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Oral and sublingual in separate experiences
Duration
Not specified clearly

The underlying illness and product identity are unverified. The commenter offered speculative explanations that are not established by the account.

Read the adverse account and follow-up

Approval status

KPV has no FDA-approved therapeutic use. The cited work is preclinical, and FDA describes a lack of human exposure data in its compounding assessment.

Preclinical evidence; no FDA approval

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Human benefits for specific gut or skin conditions
  • Long-term and uncommon adverse effects
  • Interactions and reliable product exposure

Summary

KPV belongs in the preclinical research category; an anti-inflammatory mechanism is not an established treatment benefit.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: safety concerns for selected bulk substances

    Ingredient-specific safety findings; compounding review is not drug approval.

  2. pubmedPepT1-mediated KPV uptake and intestinal inflammation

    Cell experiments and two mouse colitis models.

  3. pubmedKPV in a murine colitis-associated cancer model

    Animal treatment results; human tissue observations do not establish treatment efficacy.

How we assess sources · Suggest a correction